Detalhe da pesquisa
1.
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
N Engl J Med
; 389(6): 504-513, 2023 Aug 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37379158
2.
ALK-Fusion Transcripts Can Be Detected in Extracellular Vesicles (EVs) from Nonsmall Cell Lung Cancer Cell Lines and Patient Plasma: Toward EV-Based Noninvasive Testing.
Clin Chem
; 68(5): 668-679, 2022 05 18.
Artigo
Inglês
| MEDLINE | ID: mdl-35348673
3.
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 21(11): 1413-1422, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32979984
4.
Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Clin Chem Lab Med
; 58(2): 306-313, 2020 01 28.
Artigo
Inglês
| MEDLINE | ID: mdl-31469650
5.
hCOA3 stabilizes cytochrome c oxidase 1 (COX1) and promotes cytochrome c oxidase assembly in human mitochondria.
J Biol Chem
; 288(12): 8321-8331, 2013 Mar 22.
Artigo
Inglês
| MEDLINE | ID: mdl-23362268
6.
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.
JAMA Oncol
; 9(3): 344-353, 2023 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36520426
7.
Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy.
Am Soc Clin Oncol Educ Book
; 42: 1-18, 2022 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-35561296
8.
Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.
Clin Cancer Res
; 28(11): 2461-2473, 2022 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35394499
9.
Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation.
Cancers (Basel)
; 14(18)2022 Sep 13.
Artigo
Inglês
| MEDLINE | ID: mdl-36139605
10.
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).
J Clin Oncol
; 40(25): 2924-2933, 2022 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35576508
11.
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
J Immunother Cancer
; 10(9)2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36171009
12.
The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy.
Biomedicines
; 9(4)2021 Mar 31.
Artigo
Inglês
| MEDLINE | ID: mdl-33807260
13.
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.
Clin Cancer Res
; 27(21): 5878-5890, 2021 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34376534
14.
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.
Clin Transl Med
; 11(7): e491, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34323406
15.
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial.
J Immunother Cancer
; 9(8)2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34446577
16.
Correction: Enhanced tumorigenicity by mitochondrial DNA mild mutations.
Oncotarget
; 11(11): 1006, 2020 Mar 17.
Artigo
Inglês
| MEDLINE | ID: mdl-32215189
17.
ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib.
Transl Lung Cancer Res
; 9(3): 532-540, 2020 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-32676317
18.
Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-ß signaling.
Free Radic Biol Med
; 130: 163-173, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30391585
19.
Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition.
Free Radic Biol Med
; 135: 167-181, 2019 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30880247
20.
Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment.
Oncotarget
; 8(36): 60291-60298, 2017 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28947971